Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lymfactin in Secondary Lymphedema
NCT02994771Phase 1Terminated
- Sponsor
- Herantis Pharma
- Start
- Jun 2016
- Primary completion
- Feb 2019
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 1, open-label trial of lymfactin in secondary lymphedema (2 arms), sponsored by Herantis Pharma. Primary endpoints: Number of patients with treatment related adverse events and serious adverse events at 5 years, CT scan of chest and abdomen at 5 years and 2 more. Started Jun 2016; status: terminated.
02
Drugs
lymfactin
03
Conditions
secondary lymphedema
Beyond the preview
Go deeper on NCT02994771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02994771.